Skip to main content

The Effect of Preanalytical and Physiological Variables on Cell-Free DNA Fragmentation.

van der Pol Y, Moldovan N, Verkuijlen S, Ramaker J, Boers D, Onstenk W, de Rooij J, Bahce I, Pegtel DM, Mouliere F

Publication: Clin Chem (2022)PMID: 35292813View on PubMed

Purpose

This study investigated the effects of blood collection tube type (EDTA, PAXgene or Norgen), processing delays (< 4 h versus > 4 h), and patient condition (gender, age, BMI, health status and exercise) on cell-free DNA (cfDNA) fragmentation patterns.

Conclusion

cfDNA concentration, tumor fraction, and fragment size distribution were unaffected by the type of tube used during blood collection, although the proportion of fragments of specific sizes did differ slightly. While there was no difference in the chromosome arm fragmentation profile or fragment end diversity, specimens from healthy patients clustered separately by collection site. . The proportion of fragments that were 100-150 bp in length and fragmentation end diversity (Shannon entropy index) were comparable among specimens for which processing time was not recorded and those processed in <4 h or >4 h. However, minor significant differences in fragmentation of chromosomes 5 and 11 were found between specimens processed in <4 h and those processed after a delay >4 h.

Plasma from males had a higher proportion of fragments between 100 and 150 bp in length than female patients but no effect of patient age, body mass index, presence of a non-cancer pathology, or medication use was observed.  While no individual chromosome displayed differences in fragmentation patterns between specimens from males and females, minor differences in fragmentation of individual chromosomes were found based on patient age, medication use, health status and exercise status.

Studies (3)

Purpose

This study compared cfDNA concentrations and fragmentation among case-matched blood specimens collected in EDTA and PAXgene tubes from healthy patients and lung cancer patients at one center and between matched specimens from healthy patients collected in EDTA and Norgen tubes at a second center.  Blood was collected from each patient (five healthy patients and six patients with lung cancer) into an EDTA tube and PAXgene tube.  At a different center, case-matched blood specimens were collected from each patient (five additional healthy patients) into an EDTA tube and a Norgen tube. Plasma was isolated by centrifugation at 900 g for 7 min followed by 2500 g for 10 min within 5.5 h of blood draw.  Plasma was aliquoted and stored at -80°C. cfDNA was isolated using the QIAsymphony Circulating DNA Kit and cfDNA concentration was quantified using the Cell-free DNA ScreenTape Analysis assay on a Agilent 4200 TapeStation System. Sequencing libraries were prepared using the ThruPLEXVR Plasma-seq Kit and were 150 bp pair-end sequenced on a Illumina NovaSeq 6000. Copy number analysis was performed using the ichorCNA software and cfDNA fragment size analysis was analyzed using the Picard InsertSizeMetrics.

Summary of Findings

In healthy donors, plasma from PAXgene tubes and Norgen tubes had cfDNA concentrations that were comparable to case-matched EDTA plasma; in lung cancer patients, case-matched plasma from PAXgene tubes and EDTA tubes had comparable cfDNA concentrations. Similarly, the tumor fraction was comparable between case-matched specimens, regardless of blood collection tube type. The fragment size distribution had a mode of approximately 167 bp and a comparable proportion of fragments that were 40-150 bp in length, regardless of collection tube type, but EDTA plasma had a higher proportion of fragments that were 60-90 bp in length than case-matched PAXgene plasma (P<0.05, both) and 270, 300, 330, 360 and 390 bp fragments than Norgen plasma (all P<0.01, except 390 bp P<0.05). There were no differences in the chromosome arm fragmentation profiles among the different tube types and specimens mostly clustered by patient. However, clustering segregated patients by collection site. Fragment end analysis showed the expected overrepresentation of CCA, CCT and CCC but there was no difference in fragment end diversity between specimens from healthy patients collected in EDTA tubes and PAXgene or Norgen tubes, nor between specimens from patients with lung cancer collected in EDTA and PAXgene tubes. Interestingly, clustering based on fragment end analysis also resulted in separate clustering of specimens from healthy individuals collected in EDTA tubes at the two different collection sites.

  • Biospecimens

    FluidPlasma
  • Preservation Types

    FrozenPAXgene
  • Diagnoses

    NeoplasticCarcinoma
    Normal
  • Platforms

    DNAAutomated electrophoresis/Bioanalyzer
    DNANext generation sequencing
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Healthy patient
    Lung cancer patient
    Biospecimen AcquisitionLocale of biospecimen collection
    Two centers compared
    Biospecimen AcquisitionType of collection container/solution
    EDTA tube
    Norgen tube
    PAXgene tube